Market Overview

UPDATE: Sterne Agee Reiterates On Salix Pharmaceuticals Ltd. On FDA Panel Outcome

Related SLXP
Salix Secures Additional Intellectual Property Relating To Rifaximin
UCERIS 2mg Rectal Foam For The Induction Of Remission Of Mild-To-Moderate Distal Ulcerative Colitis Granted Tentative Approval By FDA

In a report published Friday, Sterne Agee analyst Shibani Malhotra reiterated a Buy rating on Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), and raised the price target from $126.00 to $130.00.

In the report, Sterne Agee noted, “The outcome of today's FDA Panel on mu opioid antagonists, although not conclusive, suggests that Salix likely has a path to approval for Relistor for the treatment of opioid-induced constipation in non-cancer pain patients. This could potentially add an incremental $500mn-$750mn in product sales. Per our calculations, each $100mn in Relistor sales equates to $2-$3 in fair value for SLXP. We expect further insight into the future of Relistor tomorrow, as Salix's partner on the drug, Progenics Pharmaceuticals (PGNX, $4.22, Not Rated) is hosting a call on this topic.”

Salix Pharmaceuticals Ltd. closed on Thursday at $113.80.

Latest Ratings for SLXP

DateFirmActionFromTo
Sep 2014Canaccord GenuityMaintainsBuy
Sep 2014Credit SuisseInitiates Coverage onUnderperform
Aug 2014JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for SLXP
View the Latest Analyst Ratings

Posted-In: Shibani Malhotra Sterne AgeeAnalyst Color Price Target Analyst Ratings

 

Related Articles (SLXP)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters